AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Industry Workshops

The following Industry Workshop presentations will be held in the Exhibit Hall Theater during 2016 AACC Clinical Lab Expo hours, August 2 through August 4. These 60-minute sessions are conveniently presented in a theater built right inside the Pennsylvania Convention Center exhibit hall and may offer continuing education credits.


LDT Validation: YES! It Really Can Be Done!

Mass spectrometry is a key factor in developing a urine drug testing laboratory operation.  Validation is often discussed in terms of liquid chromatography-mass spectrometry.  Both topics often lead to a misunderstanding of what is really involved in establishing a laboratory developed test.  Quasar’s experiences illustrate that a better understanding can greatly reduce the stress by refocusing on a more complete understanding of validation, and creating success by examining components in the process.  Concrete examples of successful lab startups and lessons learned are provided for greater insight.

Low ALP Matters: Alkaline Phosphatase, Why It’s Important, and Its Role in the Diagnosis of Hypophosphatasia

Hypophosphatasia is a devastating, rare disease that affects patients of all ages, for which a therapy is now available.  Low alkaline phosphatase is the biochemical hallmark of HPP.  This session will describe the relationship between low ALP and HPP, and especially for children, the importance of using appropriately age-and gender-adjusted ALP reference ranges to interpret results. 

Get Behind the Scenes of Population Health With AACC and LabLeaders

LabLeaders was created to redefine the value of the laboratory.  Early in 2016, AACC and LabLeaders came together to make this goal a reality through an interactive roundtable focused on providing key insights into how healthcare reform and accountable care organizations are impacting labs of today and will affect those of tomorrow. For a full, behind-the-scenes access to these engaging insights, join us live at the LabLeaders Industry Workshop. 

Innovation for Health: Utilization of Metagenomic Technology to Discover a Novel Human Pegivirus Associated with Hepatitis C Virus Co-Infection

Identification of novel pathogens drives innovation in laboratory diagnostics and has a tremendous impact on human health.  This workshop will focus on emerging metagenomic approaches for pathogen discovery utilizing next-generation sequencing and pan-viral DNA array technology.  In contrast to currently available diagnostics tests, narrowly targeted to specific pathogens, these state-of-the-art genomic approaches utilize “random-priming” of nucleic acid in clinical specimens to provide comprehensive coverage of both known and unknown pathogens.  Speakers at this Industry Workshop will describe successful implementation of metagenomic NGS to discover and characterize a novel human virus (provisionally named human pegivirus 2) associated with Hepatitis C Virus infection. 

Adoption of New Biomarkers and Technologies for Antiphospholipid Syndrome Testing

This session will include an overview of different methodologies to detect antiphospholipid syndrome antibodies as well as new biomarkers for APS and their clinical utility. 

Lab Automation and New Solutions to Address the Challenges of Hemostasis Testing

Historically, laboratory automation focused in areas of chemistry and hematology in which improved turnaround times and standardized processes enhanced overall lab efficiency. Until recently, automation of hemostasis testing was limited to a few routine tests, while automation of a broader range, including specialty hemostasis testing, was not feasible due to specific sample preparation requirements and results interpretation. This workshop focuses on the benefits of automating hemostasis testing and how it can now be successfully implemented for both routine and specialty testing.


Current Laboratory Trends in Successful Graves’ Disease Management

Hyperthyroidism affects approximately 1.5% of the worldwide population. Graves’ disease is the most common cause of hyperthyroidism, and accounts for 60 to 80 % of all cases. It is an autoimmune disorder caused by thyroid stimulating antibody, activity against the thyroid-stimulating hormone (receptor. This stimulates the thyroid gland to synthesize and secrete excess thyroid hormone. Being able to diagnose the cause of hyperthyroidism quickly and accurately is critical to the quality of patient care.

Improving Quality and Turnaround Time of Clinical Chemistry Specimens Using Plasma

Hospital-based clinical laboratories are increasingly moving from serum to plasma samples in order to support improved turnaround times.  However, interferences from pre-analytical variables such as cellular contamination can pose a challenge to reporting accurate results.  During this interactive session, speakers Mitchell Scott, PhD, of Washington University School of Medicine and Martin Fleisher, PhD, of Memorial Sloan-Kettering Cancer Center will discuss how converting from serum to plasma samples improved the efficiency of their clinical laboratories as well as the challenges they face.  Sol Green, PhD, from BD also will describe a new plasma separation technology that uses a mechanical separator in lieu of gel.

Driving Clinical Value through Lab Testing – Case Studies with Cardiac and Sepsis Biomarkers

Driving clinical decisions with reliable and accurate testing is key to engaging clinicians and improving patient outcomes.  This session will provide examples of how best to accomplish this using Roche Cardiac solutions. 

Natriuretic Peptides (NPs): Understanding Your Options

Natriuretic peptides play an integral role in the diagnosis of congestive heart failure.  Laboratories today have the ability to choose between NT-proBNP and BNP assays to support the testing needs of their patient population. 

Clinical Impact of Sample Quality and the Value of Automating Pre-Analytical Quality Assurance in Hemostasis Testing

Technological advancements and new reagents have improved the accuracy and turnaround times in hemostasis testing.  Unfortunately, labs are still challenged with identifying and managing pre-analytical sample issues.  Under-filled sample tubes and samples containing interfering levels of hemolysis, icterus, and lipemia are the most common issues.  This workshop will explore these and other pre-analytical sample challenges and their impact on the accuracy of hemostasis testing.  New techniques and technology to automate the detection and management of suboptimal samples and ensure quality of results will also be discussed.  

Measuring the Unmeasured: Direct Oral Anticoagulants - Views from Beyond the Lab

Indirectly acting oral anticoagulant medications such as warfarin require routine laboratory or near-patient test monitoring.  However, since 2009, direct oral anticoagulants not requiring routine monitoring have been available in clinical practice to reduce risk of stroke in atrial fibrillation patients, and to prevent or treat deep vein thrombosis and pulmonary embolism.  However, situations in which a DOAC test could be helpful for patient management have been reported in clinical guidelines.  In this educational session, those situations will be outlined along with potential laboratory based testing solutions. 

Proteins: Not Just for Carnivores ― Digesting the Latest in Special Protein Testing

This workshop introduces key factors in special protein testing, including the latest trends and innovations.  We will explore the experiences of two laboratories, including their data and observations, workflow, ease-of-use, efficiency and overall cost.


How a Comprehensive Laboratory Approach to Monitoring Bleeding Events Leads to Better Patient Outcomes and Healthier Hospitals

Presentation 1: Measuring Direct Oral Anticoagulants in the Laboratory
A number of novel, oral anticoagulant agents have been introduced recently. These include both direct thrombin and direct factor Xa inhibitors. The impact of these new agents on different activated partial thromboplastin time and prothrombin time reagents and the utility of these assays as well as the thrombin time, in discerning drug presence will be discussed. Assays specific for measuring these anticoagulants will be introduced. These anticoagulants also impact many coagulation assays leading to spurious results and this impact will be reviewed. 

Presentation 2: Clinical Consequences of Inaccurate Platelet Counts 
Decisions regarding prophylactic platelet transfusions are largely based on platelet count, therefore platelet count accuracy is very important. Contemporary automated optical and impedance platelet counting methods, while reliable for the majority of samples tested, have been shown to be suspect in severely thrombocytopenic patients, usually those eligible for platelet transfusion. Compounding the problem is that the accuracy and precision of optical and impedance methods diminishes when interferences such as fragmented red blood cells and large/giant platelets are present. Further, platelet count biases due to these interferences are highest when the platelet count is very low. 

This presentation will review original data which shows the degree of inaccuracy found in optical and impedance methods currently available on four different hematology analyzers. In addition, the potential impact on transfusion decisions will be shown in each case. The results should be eye-opening.